Over the past decade, there have been major advancements in the field of precision medicine, leading to exciting new treatments for some cancer patients. Much attention has been focused on genomic profiling of tumors to identify genomic alterations that might guide selection of specific therapies for individual patients. Beyond genomics, however, there is a variety of other precision approaches that can identify and exploit cancer-specific biological mechanisms including proteomics, metabolomics, and computational modeling, resulting in the more effective use of existing cancer medicines. On Thursday, December 13, 2018, the MIT Center for Precision Cancer Medicine will hold its inaugural annual symposium in the Samberg Conference Center at MIT. This full-day event will feature leading researchers and clinicians, who will highlight recent advances in precision cancer medicine and share perspectives on the future. An industry panel will also discuss the barriers to instituting precision medicine into current and future clinical trials.
For sponsorship opportunities and additional information, please contact Leny Gocheva.
Keynote Address
![]() |
Lineage Plasticity in Prostate CancerCharles Sawyers, MDChair, Human Oncology and Pathogenesis Program |
Speakers
![]() |
A Mechanistic Framework for the Systematic Pharmacological Targeting of Non-Oncogene Dependencies: Towards a More “Precise” Implementation of Precision OncologyAndrea Califano, PhDClyde and Helen Wu Professor of Chemical Systems Biology, Columbia University |
![]() |
Advancing Technologies for Discovery and Production in Precision MedicineJ. Christopher Love, PhDProfessor of Chemical Engineering, MIT |
![]() |
Precision Medicine in Melanoma: Are We There Yet?Richard Marais, PhDProfessor of Molecular Oncology |
![]() |
Precision Cancer Medicine: Neither Silver Bullet Nor an IllusionKenna Mills Shaw, PhDExecutive Director |
![]() |
Evolution of Drug Resistance in Oncogene-Driven Lung CancerAlice Shaw, MD, PhDProfessor, Harvard Medical School |
![]() |
Targeting Metabolism in CancerMatthew Vander Heiden, MD, PhDAssociate Professor of Biology, MIT |
![]() |
Using Systems Biology of DNA-damage Signaling to Improve Cancer TreatmentMichael B. Yaffe, MD, PhDDavid H. Koch Professor of Science, MIT |
![]() |
Integrating Immunotherapy and Targeted Therapies in Cancer Treatment: From Mouse Models to Human TherapiesJean Zhao, PhDProfessor of Biological Chemistry and Molecular Pharmacology |
Panelists: Barriers to Instituting Precision Medicine in Clinical Trials
![]() |
Peter Hammerman, MD, PhDGlobal Head, Translational Research |
![]() |
Steffan N. Ho, MD, PhDVice President, Head of Translational Oncology |
![]() |
Shiva Malek, PhDDirector and Principal Scientist |
![]() |
Kevin Marks, PhDVP of Biology |
![]() |
S. Michael Rothenberg, MD, PhDVice-President, Research and Development |
![]() |
ModeratorAngela Koehler, PhDGoldblith Career Development Professor in Applied Biology, MIT |
Thank you to our sponsors
Gold
Thermo Fisher Scientific
Silver
Takeda
Bronze
Agilent Technologies
Cell Signaling Technology